Literature DB >> 25777324

Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation.

J R Diaz-Siso1, S Fischer, G C Sisk, E Bueno, M Kueckelhaus, S Talbot, M J Carty, N S Treister, F Marty, E L Milford, B Pomahac, S G Tullius.   

Abstract

Current immunosuppression in VCA is largely based on the experience in solid organ transplantation. It remains unclear if steroids can be reduced safely in VCA recipients. We report on five VCA recipients who were weaned off maintenance steroids after a median of 2 months (mean: 4.8 months, range 2-12 months). Patients were kept subsequently on a low dose, dual maintenance consisting of tacrolimus and mycophenolate mofetil/mycophenloic acid with a mean follow-up of 43.6 months (median = 40 months, range 34-64 months). Early and late acute rejections responded well to temporarily augmented maintenance, topical immunosuppression, and/or steroid bolus treatment. One late steroid-resistant acute rejection required treatment with thymoglobulin. All patients have been gradually weaned off steroids subsequent to the treatment of acute rejections. Low levels of tacrolimus (<5 ng/mL) appeared as a risk for acute rejections. Although further experience and a cautious approach are warranted, dual-steroid free maintenance immunosuppression appears feasible in a series of five VCA recipients. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research / practice; drug toxicity; immunosuppressant; steroid; vascularized composite and reconstructive transplantation

Mesh:

Substances:

Year:  2015        PMID: 25777324     DOI: 10.1111/ajt.13103

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  12 in total

Review 1.  Outcomes after hand and upper extremity transplantation.

Authors:  Jaimie T Shores; Veronika Malek; W P Andrew Lee; Gerald Brandacher
Journal:  J Mater Sci Mater Med       Date:  2017-03-30       Impact factor: 3.896

Review 2.  Building a Hand and Upper Extremity Transplantation Program: Lessons Learned From the First 20 Years of Vascularized Composite Allotransplantation.

Authors:  Shaun D Mendenhall; Stav Brown; Oded Ben-Amotz; Michael W Neumeister; L Scott Levin
Journal:  Hand (N Y)       Date:  2018-07-31

3.  Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair.

Authors:  Kelly Walton; Kirsti Walker; Megan Riddle; Brent H Koehn; Jordan Reff; Elizabeth M Sagatys; Michael A Linden; Joseph Pidala; Jongphil Kim; Marie C Lee; John V Kiluk; Jane Yuet Ching Hui; Sang Y Yun; Yan Xing; Heather Stefanski; Harshani R Lawrence; Nicholas J Lawrence; Jakub Tolar; Claudio Anasetti; Bruce R Blazar; Said M Sebti; Brian C Betts
Journal:  Am J Transplant       Date:  2021-11-08       Impact factor: 9.369

4.  Codominant Role of Interferon-γ- and Interleukin-17-Producing T Cells During Rejection in Full Facial Transplant Recipients.

Authors:  T J Borges; J T O'Malley; L Wo; N Murakami; B Smith; J Azzi; S Tripathi; J D Lane; E M Bueno; R A Clark; S G Tullius; A Chandraker; C G Lian; G F Murphy; T B Strom; B Pomahac; N Najafian; L V Riella
Journal:  Am J Transplant       Date:  2016-04-07       Impact factor: 8.086

Review 5.  Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration.

Authors:  Maximilian Kueckelhaus; Sebastian Fischer; Midas Seyda; Ericka M Bueno; Mario A Aycart; Muayyad Alhefzi; Abdallah ElKhal; Bohdan Pomahac; Stefan G Tullius
Journal:  Transpl Int       Date:  2015-09-14       Impact factor: 3.782

6.  The Evolving Clinical Presentation of Acute Rejection in Facial Transplantation.

Authors:  Valentin Haug; Branislav Kollar; Doha Obed; Harriet Kiwanuka; Marvee Turk; Luccie Wo; Sotirios Tasigiorgos; Maximillian Kueckelhaus; Leonardo V Riella; Bohdan Pomahac
Journal:  JAMA Facial Plast Surg       Date:  2019-07-01       Impact factor: 4.611

Review 7.  Composite tissue allotransplantation: opportunities and challenges.

Authors:  Jasper Iske; Yeqi Nian; Ryoichi Maenosono; Max Maurer; Igor M Sauer; Stefan G Tullius
Journal:  Cell Mol Immunol       Date:  2019-03-06       Impact factor: 11.530

8.  Blood proteome profiling using aptamer-based technology for rejection biomarker discovery in transplantation.

Authors:  Andrey V Shubin; Branislav Kollar; Simon T Dillon; Bohdan Pomahac; Towia A Libermann; Leonardo V Riella
Journal:  Sci Data       Date:  2019-12-09       Impact factor: 6.444

9.  MMP3 Is a Non-invasive Biomarker of Rejection in Skin-Bearing Vascularized Composite Allotransplantation: A Multicenter Validation Study.

Authors:  Branislav Kollar; Audrey Uffing; Thiago J Borges; Andrey V Shubin; Bruno T Aoyama; Céline Dagot; Valentin Haug; Martin Kauke; Ali-Farid Safi; Simon G Talbot; Emmanuel Morelon; Stéphanie Dakpe; Bohdan Pomahac; Leonardo V Riella
Journal:  Front Immunol       Date:  2019-11-29       Impact factor: 7.561

10.  Increased levels of circulating MMP3 correlate with severe rejection in face transplantation.

Authors:  Branislav Kollar; Andrey Shubin; Thiago J Borges; Sotirios Tasigiorgos; Thet Su Win; Christine G Lian; Simon T Dillon; Xuesong Gu; Iris Wyrobnik; George F Murphy; Bohdan Pomahac; Towia A Libermann; Leonardo V Riella
Journal:  Sci Rep       Date:  2018-10-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.